Circulating nucleic acids as a potential source for cancer biomarkers
- PMID: 20196731
- DOI: 10.2174/156652410790963295
Circulating nucleic acids as a potential source for cancer biomarkers
Abstract
Since the association of circulating DNA level changes with tumor growth was discovered many attempts have been made to develop the sensitive and robust blood-based tests for early tumor diagnostics. Both genomic as well as mitochondrial DNA quantification in the circulation have been extensively evaluated as a diagnostic and prognostic tool to monitor cancer therapy. Cell-free DNA bearing the same genetic and epigenetic changes as the tumor tissues were shown to be detectable in plasma / serum of cancer patients indicating the principal possibility to create the minimally invasive diagnostic tests based on tumor-specific DNA markers. Apart from circulating DNA, tumor-derived RNA in plasma / serum was found to be a promising approach for the development of cancer markers. Results of the last two years establish the quantification of the tumor-derived microRNAs in plasma / serum as an extremely promising approach for cancer diagnostics. The aim of this publication was to review the recently reported studies on the circulating DNA and RNA in cancer patients and to estimate their impact on making the ongoing research closer to clinical application.
Similar articles
-
Circulating nucleic acids in plasma or serum (CNAPS) as prognostic and predictive markers in patients with solid neoplasias.Dis Markers. 2005;21(3):105-20. doi: 10.1155/2005/218759. Dis Markers. 2005. PMID: 16276004 Free PMC article. Review.
-
Circulating nucleic acids as a tumor marker.Histol Histopathol. 2002;17(3):937-43. doi: 10.14670/HH-17.937. Histol Histopathol. 2002. PMID: 12168805 Review.
-
Circulating nucleic acids in plasma or serum.Clin Chim Acta. 2001 Nov;313(1-2):143-6. doi: 10.1016/s0009-8981(01)00666-0. Clin Chim Acta. 2001. PMID: 11694252
-
Circulating cell-free nucleic acids as biomarkers in colorectal cancer screening and diagnosis.Expert Rev Mol Diagn. 2016;16(2):239-52. doi: 10.1586/14737159.2016.1132164. Epub 2016 Jan 18. Expert Rev Mol Diagn. 2016. PMID: 26652067 Review.
-
Diagnostic potential of circulating nucleic acids for oncology.Expert Rev Mol Diagn. 2003 Jul;3(4):431-42. doi: 10.1586/14737159.3.4.431. Expert Rev Mol Diagn. 2003. PMID: 12877383 Review.
Cited by
-
Emerging molecular biomarkers--blood-based strategies to detect and monitor cancer.Nat Rev Clin Oncol. 2011 Mar;8(3):142-50. doi: 10.1038/nrclinonc.2010.220. Nat Rev Clin Oncol. 2011. PMID: 21364687 Review.
-
Exploring the impact of EGFR T790M neighboring SNPs on ARMS-based T790M mutation assay.Oncol Lett. 2016 Nov;12(5):4238-4244. doi: 10.3892/ol.2016.5184. Epub 2016 Sep 26. Oncol Lett. 2016. PMID: 27895798 Free PMC article.
-
Biomedical diagnosis perspective of epigenetic detections using alpha-hemolysin nanopore.AIMS Mater Sci. 2015;2(4):448-472. doi: 10.3934/matersci.2015.4.448. Epub 2015 Nov 16. AIMS Mater Sci. 2015. PMID: 30931380 Free PMC article.
-
MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes mellitus.PLoS One. 2011;6(8):e22839. doi: 10.1371/journal.pone.0022839. Epub 2011 Aug 1. PLoS One. 2011. PMID: 21829658 Free PMC article.
-
Colorectal cancer: from prevention to personalized medicine.World J Gastroenterol. 2014 Jun 14;20(22):6786-808. doi: 10.3748/wjg.v20.i22.6786. World J Gastroenterol. 2014. PMID: 24944469 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources